Novel therapies in development for the treatment of traumatic brain injury
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In industrialised countries, the mean per capita incidence of traumatic brain injury (TBI) that results in a hospital presentation is 250 per 100,000. In Europe and North America alone, this translates to > 2 million TBI presentations annually. Approximately 25% of these presentations are admitted for hospitalisation. Despite the significance of these figures, there is no single interventional pharmacotherapy that has shown efficacy in the treatment of clinical TBI. This lack of efficacy in clinical trials may be due, in part, to the inherent heterogeneity of the traumatic brain injury population. However, it is the multifactorial nature of secondary injury that also poses a major hurdle, particularly for those therapies that have been designed to specifically target an individual injury factor. It is now becoming increasingly recognised that any successful TBI therapy may have to simultaneously affect multiple injury factors, somewhat analogous to other broad spectrum interventions. Recent efforts in experimental TBI have therefore focussed on developing novel pharmacotherapies that may affect multiple injury factors and thus improve the likelihood of a successful outcome. While a number of interventions are noteworthy in this regard, this review will focus on three novel compounds that show particular promise: magnesium, substance P antagonists and cyclosporin A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Role of Excitatory Amino Acids and NMDA Receptors in Traumatic Brain Injury
Faden, A. I., Demediuk, P., Panter, S. S., & Vink, R. (1989) · Science · doi:10.1126/science.2567056 · Cited by 1,508
Self-citationClinical trials in head injury
Narayan, R. K., Michel, M. E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M. B., Bullock, M. R., Choi, S. C., Clifton, G. L., Contant, C. F., et al. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754037 · Cited by 913 · cited 2×
“Interested readers are referred to some excellent analyses of these trials that have been reviewed elsewhere [2-4].”
BackgroundFactors affecting excitatory amino acid release following severe human head injury
Bullock, R., Zauner, A., Woodward, J. J., Myseros, J., Choi, S. C., Ward, J. D., Marmarou, A., & Young, H. F. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.89.4.0507 · Cited by 526
Energy Metabolism during Apoptosis
Garland, J. M., & Halestrap, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.8.4680 · Cited by 207
Cited by
Clinical trials in head injury
Narayan, R. K., Michel, M. E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M. B., Bullock, M. R., Choi, S. C., Clifton, G. L., Contant, C. F., et al. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754037 · Cited by 913
Incidence of traumatic brain injury in New Zealand: a population-based study
Feigin, V. L., Theadom, A., Barker-Collo, S., Starkey, N. J., McPherson, K., Kahan, M., Dowell, A., Brown, P., Parag, V., Kydd, R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70262-4 · Cited by 729
Pathophysiology of Cerebral Ischemia and Brain Trauma: Similarities and Differences
Bramlett, H. M., & Dietrich, W. D. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000111614.19196.04 · Cited by 631
Cernak, I. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.410 · Cited by 462
Metadata
- Authors
- Vink, R., & Nimmo, A. J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2002-10
- Volume
- 11
- Issue
- 10
- Pages
- 1375-1386
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1970845004
- Cited by
- 40
- References
- 4
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel therapies in development for the treatment of traumatic brain injury. https://app.cochat.ai/papers/10.1517/13543784.11.10.1375
- The paper
- Vink, R., & Nimmo, A. J. (2002). Novel therapies in development for the treatment of traumatic brain injury. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.11.10.1375
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.